Table 2.
Treatment modalities and outcome according to each fungal isolates.
| Type of fungal (n) | Vision at presentation | Vision posttreatment | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <6/18 | 6/18–1/60 | CF-PL | NPL | Treatment | less than 6/18 | 6/18–1/60 | CF-PL | NPL | |
| Hyaline | |||||||||
| Fusarium sp. (19) | 6 | 4 | 9 | G. Natamycin if available, G. Amphotericin. B, Oral & Gut Fluconazole. 5 PK, 1 evisceration | 10 | 3 | 4 | 2 | |
| Aspergillus sp. (4) | 1 | 3 | G. Natamycin, Voriconazole, Amphotericin B Oral Fluconazole. 1 scleral patch, 2 PK |
3 | 1 | ||||
|
Scedosporium sp. (1) |
1 | Gutt Amphotericin B & Voriconazole. Oral Voriconazole. | 1 | ||||||
| Trichoderma sp. (1) | 1 | Gutt. Ciprofloxacin (Provisional diagnosis: marginal keratitis) | 1 | ||||||
| Epidermophyton sp. (1) | 1 | Gutt. Amphotericin B & Fluconazole. Oral Fluconazole. | 1 | ||||||
|
| |||||||||
| Yeast | |||||||||
|
Candida albicans (2) (1 immunocompromised patient with bilateral involvement) |
1 | 1 | Gutt Amphotericin B | 1 | 1 | ||||
| Candida parapsilosis (2) | 1 | 1 | Gutt Amphotericin B | 1 | 1 | ||||
| (infected cornea graft) | Repeat penetrating keratoplasty | ||||||||
| Candida tropicalis (1) | 1 | Gutt Amphotericin B | 1 | ||||||
| (Ocular ischaemic syndrome) | |||||||||
|
| |||||||||
| Dermatiaceous | |||||||||
| Curvularia sp. (2) | 2 | Gutt. Amphotericin B | 2 | ||||||
|
| |||||||||
| Nonsporulating fungi (3) | 1 | 2 | Gutt. Amphotericin B | 2 | 1 | ||||
|
| |||||||||
| Unidentified hyaline (4) | 1 | 3 | All required systemic + topical treatment Natamycin in one case. One required PK. |
2 | 2 | ||||
|
| |||||||||
| Unidentified yeast (1) | 1 | Gutt Amphotericin B | 1 | ||||||
Abbreviations: CF: counting finger, PK: penetrating keratoplasty, NPL: no perception of light, PL: perception of light.